1. Home
  2. DSGN vs FACT Comparison

DSGN vs FACT Comparison

Compare DSGN & FACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • FACT
  • Stock Information
  • Founded
  • DSGN 2017
  • FACT 2024
  • Country
  • DSGN United States
  • FACT United States
  • Employees
  • DSGN N/A
  • FACT N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • FACT
  • Sector
  • DSGN Health Care
  • FACT
  • Exchange
  • DSGN Nasdaq
  • FACT NYSE
  • Market Cap
  • DSGN 208.9M
  • FACT 245.6M
  • IPO Year
  • DSGN 2021
  • FACT 2024
  • Fundamental
  • Price
  • DSGN $3.67
  • FACT $10.29
  • Analyst Decision
  • DSGN Hold
  • FACT
  • Analyst Count
  • DSGN 1
  • FACT 0
  • Target Price
  • DSGN $4.00
  • FACT N/A
  • AVG Volume (30 Days)
  • DSGN 89.5K
  • FACT 110.1K
  • Earning Date
  • DSGN 08-04-2025
  • FACT 01-01-0001
  • Dividend Yield
  • DSGN N/A
  • FACT N/A
  • EPS Growth
  • DSGN N/A
  • FACT N/A
  • EPS
  • DSGN N/A
  • FACT N/A
  • Revenue
  • DSGN N/A
  • FACT N/A
  • Revenue This Year
  • DSGN N/A
  • FACT N/A
  • Revenue Next Year
  • DSGN N/A
  • FACT N/A
  • P/E Ratio
  • DSGN N/A
  • FACT N/A
  • Revenue Growth
  • DSGN N/A
  • FACT N/A
  • 52 Week Low
  • DSGN $2.60
  • FACT $9.85
  • 52 Week High
  • DSGN $7.77
  • FACT $10.32
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 48.40
  • FACT N/A
  • Support Level
  • DSGN $3.65
  • FACT N/A
  • Resistance Level
  • DSGN $4.21
  • FACT N/A
  • Average True Range (ATR)
  • DSGN 0.23
  • FACT 0.00
  • MACD
  • DSGN -0.00
  • FACT 0.00
  • Stochastic Oscillator
  • DSGN 23.81
  • FACT 0.00

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About FACT FACT II ACQUISITION CORP

FACT II Acquisition Corp is a blank check company.

Share on Social Networks: